Chinese Academy of Sciences

Haining Hu

Fajun Nan

Min Li

Yangming Zhang

Haiyan Xu

Zhaobing Gao

Huanan Liu

Xiaoping Pi

Sheng Liu

Fei Chen

Pingzheng Zhou

The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window. 

KCNQ potassium channel agonist, and preparation method therefor and use thereof

KCNQ potassium channel agonists, method of preparation and method of use thereof

The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration. 

Compound as KCNQ potassium channel agonist, preparation method therefor and use thereof

Growing community of inventors

Shanghai, China

Haining Hu